Overview

The implementation of initiatives aimed at curbing unintended pregnancies, reducing associated healthcare expenditure, and the subsequent growth in user awareness levels are expected to continue driving the contraceptives industry over the forecast period.

According to the U.S. Centers for Disease Control and Prevention (CDC) and other reproductive health organizations, nearly half (approximately 45–46%) of all pregnancies in the U.S. are still classified as unintended (either unwanted or occurring too soon). While the overall pregnancy rate in the U.S. has reached a historic low, the proportion of unintended pregnancies has remained stubbornly high, with some recent data suggesting 25.5% of women with a recent live birth did not want to become pregnant or wanted to become pregnant later. Despite advancements in technology and substantial annual R&D investment, the U.S. unintended pregnancy rate remains a significant public health challenge, underscoring the persistent need for better access and adherence to effective methods. U.S. federal policy has continued to emphasize measures to increase contraceptive availability, notably through the mandated coverage by health insurance companies and the recent approval of an Emergency Contraceptive (EC) for Over-The-Counter (OTC) availability, significantly reducing access barriers.

The Global Contraceptive Market (drugs and devices combined) has experienced significant expansion. The market size is now estimated to be valued between US$19.79 billion and US$31.1 billion in 2025 (depending on the inclusion of devices or drugs alone). This market is projected to grow robustly, with a Compound Annual Growth Rate (CAGR) ranging from 5.3% to 8.4% through the forecast period (typically up to 2032–2035), indicating sustained and accelerated market momentum, largely driven by the increasing global emphasis on reproductive health and family planning.